Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable <i>RAS</i> Wild-Type Colorectal Cancer: OGSG 1602Tetsuji Terazawa, Taroh Satoh, Yoshinori Kagawa et al.|The Oncologist|2020Cited by 19
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, <i>RAS</i> wild-type colorectal cancer: OGSG 1602.Katsuya Ohta, Takeshi Kato, Masahiro Goto et al.|Journal of Clinical Oncology|2020Cited by 2
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with <i>RAS</i> Wild-type Colorectal Cancer: OGSG 1602 Final ResultsTetsuji Terazawa, Taroh Satoh, Takeshi Kato et al.|The Oncologist|2022Cited by 2
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, <i>RAS</i> wild type colorectal cancer: OGSG 1602, survival update data.Shingo Noura, Takeshi Kato, Tetsuji Terazawa et al.|Journal of Clinical Oncology|2021Cited by 0